Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

High materiality8/10

Rigel Q2 results advance with VEPPANU launch and R289 progress

Aug 4, 2026, 4:03 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Strong quarterly results, a major licensing deal with VEPPANU, and raised 2026 guidance provide tangible near-term upside catalysts. The US launch in Aug 2026 could re-rate the stock if addressable market expands and early prescriptions materialize.

AI summary

What happened, with direct paths to the underlying reporting

Rigel reported Q2 2026 revenues of $78.7M and net income of $17.3M, led by TAVALISSE. It closed VEPPANU licensing with a $70M upfront and expects U.S. availability mid-August 2026. The 2026 outlook rose to $285–$295M, while the R289 Phase 1b program advances with data anticipated by year-end.

Q2 2026 total revenues $78.7M; net income $17.3M.
VEPPANU licensing with Arvinas/Pfizer; US availability mid-August 2026; $70M upfront.
R289 Phase 1b enrollment on track; dose expansion data and dose selection in 2H26.
2026 outlook raised to $285–$295M; net product $255–$265M; contract ~$30M.
Alison L. Hannah, M.D. appointed Executive VP and Chief Medical Officer.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Rigel Q2 results advance with VEPPANU launch and R289 progress

This biotech stock has jumped nearly 50% in 3 months. Its CEO says business is 'growing substantially'

Rigel Pharmaceuticals: Undervalued FDA-Approved Products With Promising Cash Flow Potential